ABSTRACT. Cytochrome P4502E1 (CYP2E1) is a key enzyme in the metabolic activation of many carcinogens, but the roles of CYP2E1 polymorphisms in cervical neoplasia (CN) are inconclusive. Published case-control cohort studies from the Pubmed, Embase, and China National Knowledge Infrastructure databases were retrieved. Data were extracted and pooled odds ratios with 95% confidence intervals were calculated. Seven studies examining 1097 cases and 1117 controls were included in this meta-analysis. The pooled effect size showed no association between CYP2E1 RsaI and DraI polymorphisms and CN risk in a codominant model. However, using a recessive model, an association between the PstI polymorphism and CN risk was observed (odds ratio: 2.10, 95% confidence interval: 0.96-4.62, P = 0.06), indicating that individuals with the homozygous rare genotype have a higher risk of developing CN compared to those with homozygous wildtype and heterozygous genotypes. When stratified by ethnicity, the PstI polymorphism was significantly correlated with CN susceptibility in non-Asians (odds ratio: 3.74, 95% confidence interval: 1.13-12.43, P = 0.03). This meta-analysis suggests that the CYP2E1 PstI polymorphism increases the risk of CN in non-Asians.
INTRODUCTION
Cytochrome P4502E1 (CYP2E1) is a member of the cytochrome P450 superfamily and a key enzyme in the metabolic activation of many carcinogens. The DraI, PstI, and RsaI restriction fragment length polymorphism patterns of the CYP2E1 gene are associated with a predisposition to cancer in humans (Agundez, 2004) .
Cervical cancer is the second most common type of cancer among women worldwide. In addition to other risk factors (human papilloma virus infections, chemical reagents exposure, etc.), genetic background independently plays an important role in this process . Over the past decade, several studies have focused on the relationship between CYP2E1 gene polymorphisms and cervical neoplasia (CN), including high-grade squamous intraepithelial lesion, cervical intraepithelial neoplasia, carcinoma in situ, and invasive cervical cancer (Kim et al., 2000; Ferreira et al., 2006; Sierra-Torres et al., 2003 Nishino et al., 2008; Liu et al., 2009; von Keyserling et al., 2011) . However, the results were not conclusive. In this study, we performed a meta-analysis to determine the relationship between CYP2E1 gene polymorphisms and CN risk.
MATERIAL AND METHODS

Search strategy
A literature search was conducted using the Pubmed, Embase, and China National Knowledge Infrastructure (www.cnki.net) databases. The following search terms were utilized: cytochrome P4502E1 or CYP2E1, and gene polymorphism or polymorphism or variant, and cervical squamous intraepithelial lesion or cervical intraepithelial neoplasia or cervical neoplasia or cervical carcinoma or cervical cancer.
Data extraction
Two independent reviewers collected the data according to inclusion and exclusion criteria. For inclusion in the meta-analysis, retrieved articles had to state the number of cases and controls and number of individual genotypes in cases and controls. Exclusion criteria in the meta-analysis were: 1) not a genetic study, 2) duplicated report, and 3) no useful data reported. Unpublished data were not considered. Disagreement was resolved by discussion before reaching a consensus.
Statistical analyses
Categorical variables were presented as the odds ratio (OR) with 95% confidence interval (CI). For CYP2E1 DraI, PstI, and RsaI polymorphisms, the 3 different genotypes were referred to as the homozygous wild-type genotype (c1c1), heterozygous genotype (c1c2), and homozygous rare genotype (c2c2), respectively. OR1, OR2, and OR3 were calculated as follows: 1) c2c2 vs c1c1; 2) c1c2 vs c1c1; 3) c2c2 vs c1c2. Pairwise differences (OR1, OR2, and OR3) were used to identify the most appropriate genetic model as previously described (Chen et al., 2013) . Pooled ORs with 95%CIs were calculated and P < 0.05 was considered to be statistically significant. Heterogeneity was evaluated using the Q test. Meta-analysis was conducted using the fixed-effect model when there was no heterogeneity (P ≥ 0.1). Otherwise, the random-effect model was used. Subgroup analysis was performed by ethnicity. The Begg rank correlation test and the Egger linear regression test were used to identify potential publication bias. All analyses were conducted using Revman 5.0 (Cochrane Collaboration, Oxford, UK) and Stata 11.0 (StataCorp, College Station, TX, USA).
RESULTS
Studies included in the meta-analysis
Forty-two studies were relevant to the search terms. After reviewing the titles, abstracts, and articles, 35 studies were excluded, and 7 studies examining 1097 cases and 1117 controls matched the inclusion criteria (Figure 1 ). Of the 7 included studies, 6 were published in English and 1 was published in Chinese. These studies were carried out in China, Japan, Korea, USA, Portugal, Colombia, and Germany. Although the ethnicity was not indicated by Sierra-Torres et al. (2006), a non-Asian mixed population in Colombia was assumed. The main features of the included studies are presented in Table 1 . c1c1: homozygous wild-type genotype; c1c2: heterozygous genotype; c2c2: homozygous rare genotype
Quantitative synthesis
After calculating OR1, OR2, and OR3, the most appropriate genetic models for the PstI, RsaI, and DraI polymorphisms were the recessive model, codominant model, and codominant model, respectively. In the codominant model, no association was observed between the RsaI and DraI polymorphisms and CN risk (data not shown). However, using the recessive model, the pooled effect size showed an association between the PstI polymorphism and CN risk (c2c2 vs c1c1+c1c2, OR: 2.10, 95%CI: 0.96-4.62, P = 0.06, Figure 2 ), indicating that individuals with the homozygous rare genotype had a higher, but not significant, risk of CN compared to those with the homozygous wild-type genotype and heterozygous genotype. In subgroup analysis by ethnicity, the results indicated that the PstI polymorphism was significantly correlated with CN susceptibility in non-Asians (c2c2 vs c1c1+c1c2, OR: 3.74, 95%CI: 1.13-12.43, P = 0.03, Figure 2 ). 
Analyses of heterogeneity, sensitivity, and publication bias
Significant heterogeneity was not observed between all studies in c2c2 vs c1c1+c1c2 for the PstI polymorphism. When stratified by ethnicity, no heterogeneity was observed in non-Asians. After exclusion of each study, the pattern of the pooled effect size was still significant for the PstI polymorphism. Publication bias was not observed based on the Begg rank correlation test (P = 0.734) and the Egger linear regression test (P = 0.547).
DISCUSSION
CYP2E1, a key enzyme in the metabolic activation of several carcinogens, contributes to the development of CN. Recently, the association between CYP2E1 polymorphisms and CN risk has received increasing attention because of its potential in transcriptional regulation of gene expression (Agundez, 2004) . However, in this meta-analysis, the CYP2E1 RsaI and DraI polymorphisms were not found to be correlated with CN risk in a codominant model (the most ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 5203-5209 (2015) appropriate), which is consistent with the results of previous studies (Kim et al., 2000; Ferreira et al., 2006; Liu et al., 2009) .
Notably, the PstI restriction site polymorphism in the 5' flanking region of the CY-P2E1 gene has been shown to affect the transcriptional regulation of gene expression for several carcinogens (Carriere et al., 1996) , which is associated with cancer development (ElZein et al., 1997; Hildesheim et al., 1997) . Sierra-Torres et al. (2006) indicated that the PstI homozygous variant (c2/c2) conferred an overall greater than 6-fold increase in the risk for high-grade squamous intraepithelial lesion in a non-Asian population, even after adjusting for wood smoke exposure and human papillomavirus-infection; however, no significant effect of the c2/c2 genotype on the overall risk for CC was reported in a Korean population by Kim et al. (2000) , suggesting the role of PstI in CN susceptibility may depend on ethnicities.
In this meta-analysis, we observed an association between the PstI polymorphism and CN risk in a recessive model (the most appropriate) with no heterogeneity, indicating that individuals with the homozygous rare genotype (c2/c2) had a higher risk of CN than those with the homozygous wild-type genotype (c1/c1) and heterozygous genotype (c1/c2), although statistical significance was not reached. Further results confirmed that the PstI polymorphism was significantly correlated with CN susceptibility in non-Asians. Moreover, after excluding each study, the pattern of the pooled effect size remained significant. Publication bias was not suggested in the present study, possibly because of the deliberate search strategy and data extraction methods used.
However, there were some limitations to this meta-analysis. First, the sample size was small. Second, the pooled estimates were not adjusted for confounding factors. Third, lack of the original data in the studies limited further analysis.
In conclusion, although the pooled estimates should be interpreted with caution, our meta-analysis results suggest that the CYP2E1 PstI polymorphism is associated with CN risk in non-Asians. However, large sample size studies in different populations, as well as more detailed data regarding individual differences and environmental factors, are warranted.
